ASH 2025 | Top amyloidosis updates from ASH 2025: the AQUARIUS trial, CAR T-cells, bispecifics & more!

There was some really exciting data that was presented at ASH this year. Some of these were related to outcomes in the daratumumab-based area. We’ve seen that patients can have really good outcomes and daratumumab-based regimens can be well tolerated. There was an oral presentation on the Aquarius study which looked at delayed VCD with daratumumab versus upfront VCD and the delayed responses for those hematologically if you delay giving the VCD, so that’s useful for us to know about because we know we want to get deep responses as soon as possible, particularly for those with cardiac involvement. We have some exciting data on novel therapies, so those include targets such as bispecifics, and we hope that we’ll get more data on that, as well as CAR-T, which we have trials enrolling for, so that’s really exciting. These, of course, are in the relapsed/refractory setting. But we know that they’re very, very effective therapies. So responses can be very quick and deep. We would hope to see the durability of these in years to come. There was an excellent oral, again, on venetoclax, which is a potent agent in 11;14, we know, and has efficacy in amyloidosis with CR rates, which were good. They were not as impressive as we’ve seen elsewhere with bispecifics and CAR-T, but this was given as a single agent with steroids. So perhaps using this in combination with other agents in the future would be a really useful agent to use. So I think there were a number of topical areas that were of interest, and I think this is a good benchmark for future progress in the future, and it’s an exciting area to be in.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.